Proteomics Core Facility The Proteomics Core strives to provide outstanding mass spectrometry-based service and training to Cancer Center researchers. The core provides state-of-the-art analysis for protein identification from mixtures of proteins;defining post-translational modifications (i.e. phosphorylation, acetylation, ubiquitination);and quantitative analysis of changes in protein expression or modification using methods such as SILAC and ITRAQ, The core works with investigators to ensure use of the best proteomic applications for design of experimental protocols needed to answer important cancer biology-related questions and provides a unique training environment for students and fellows. Highlights of proteomic research supported by the core include papers In Cell (Salmon), Nature (Zhang), PNAS (Whang) and Molecular and Cellular Biology (Burridge, Marzluff, Patterson). The core is led by three Ph.D. scientists with extensive proteomics experience: Drs. Lee Graves (Faculty Director), Maria Hines (Facility Director) and Xian Chen (Technology Development Director). Core usage has steadily increased and reflects the fundamental need to understand proteome dynamics at an ever increasing level of sophistication. The Institution and Cancer Center has provided more than $2.5 million dollars in the past five years for new mass spectrometry and nano-LC instrumentation. The core continues to increase its capacity to perform high-throughput large scale, quantitative proteomics. To accomplish these objectives, CCSG support of $144,563 is proposed, which is approximately 30% of the projected Proteomics Core operating costs for 2010. In 2009, the core was used by 46 cancer center members (100% peer-reviewed), accounting for 86% of total core usage. The proposed budget will partially support salaries of six core personnel and sen/ice contracts for mass spectrometers. This is an approximate 19% increase in CCSG support that is needed for the expansion of large scale high-throughput, quantitative proteomics. Future plans involve expanding the mass spectrometry-based infrastructure with an additional LTQ Orbitrap for support of state-of-the-art quantitative proteomics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594156
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$202,670
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Chen, Xiu-Fei; Tian, Meng-Xin; Sun, Ren-Qiang et al. (2018) SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep 19:
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574

Showing the most recent 10 out of 1525 publications